ARWR (Arrowhead Pharmaceuticals) Other Operating Expense : $2.1 Mil (TTM As of Mar. 2025)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Other Operating Expense?

Arrowhead Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2025 was $0.5 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $2.1 Mil.

Arrowhead Pharmaceuticals's quarterly Other Operating Expense declined from Sep. 2024 ($0.6 Mil) to Dec. 2024 ($0.5 Mil) but then increased from Dec. 2024 ($0.5 Mil) to Mar. 2025 ($0.5 Mil).

Arrowhead Pharmaceuticals's annual Other Operating Expense increased from Sep. 2022 ($-0.0 Mil) to Sep. 2023 ($1.6 Mil) and increased from Sep. 2023 ($1.6 Mil) to Sep. 2024 ($1.9 Mil).

Arrowhead Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Other Operating Expense Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Other Operating Expense

Get a 7-Day Free Trial

1.62

1.94

Arrowhead Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Operating Expense	Get a 7-Day Free Trial															0.43	0.51	0.59	0.51	0.51

Arrowhead Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.1 Mil.

Arrowhead Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

0HI3:UK HDP1:Germany

Address

177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Executives

Christopher Richard Anzalone	director, officer: President and CEO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Kenneth Allen Myszkowski	officer: CFO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Patrick O'brien	officer: General Counsel	225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
James C Hamilton	other: Senior Vice President	177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Tracie Oliver	officer: Chief Commercial Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Mauro Ferrari	director	201 SOUTH LAKE AVENUE, PASADENA CA 91101
Martin Javier San	officer: Chief Medical Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105